
FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.
Oxford Expression Technologies (OET, Oxford, UK) and Eden Biodesign (Liverpool, UK) have signed a co-marketing agreement.
Oxford Expression Technologies (OET, Oxford, UK) and Eden Biodesign (Liverpool, UK) have signed a co-marketing agreement. Under the terms of the agreement, OET will offer its customers access to Eden Biodesign’s process development, clinical trial cGMP manufacturing, and analytical development services. In return, Eden Biodesign’s customers will have access to OET’s wide range of baculovirus capabilities to meet their individual protein expression requirements.






